Results 201 to 210 of about 136,452 (263)

Toward the harmonization of bioequivalence guidelines in Europe: Commentary on the state of the art and future priorities under ICH M13A for immediate‐release oral forms

British Journal of Clinical Pharmacology, EarlyView.
Domenico Nocera, Giusi Forastiero, Andrea Logreco, Alessia Proietti, Antonio Galluccio, Carlotta Lunghi, Elisabetta Poluzzi, Fabrizio De Ponti   +7 more
wiley   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

An energy-efficient Flash-SAR ADC with two-step flash structure in a 0.18 μm CMOS process. [PDF]

Sci Rep
Xue S.
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Systematic review of economic evaluations in thalassaemia screening programmes globally: developing guidance for low- and middle-income (LMIC) settings. [PDF]

BMJ Open
Massey K, Phommasone K, Mehta A, Lee VQY, Ashley EA, Mayxay M, Painter C.   +6 more
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Performance and safety of a fine-tuned small language model for pediatric emergency triage: A benchmark study. [PDF]

PLoS One
Lee EJ, Jung JY, Kim DK, Park JW, Kwak YH.   +4 more
europepmc   +1 more source

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. [PDF]

Diabetes Metab Res Rev
Jobanputra R, Sargeant JA, Plekhanova T, James E, Almaqhawi A, Webb DR, Davies MJ, Yates T.   +7 more
europepmc   +1 more source

Comparative physiology of the brain and comparative psychology.

, 1900
openaire   +2 more sources

Screening and comprehensive analysis of endoplasmic reticulum stress-related biomarkers in atherosclerosis. [PDF]

PLoS One
Qu X, Shao Y, Li H, Bao Y, Sun Z, Yu S.
europepmc   +1 more source